Yura Mareev

  • Citations Per Year
Learn More
Guidelines give a strong recommendation for cardiac resynchronization therapy (CRT) for selected patients with heart failure. These recommendations are relatively complex and could be improved and simplified in the light of new data. In this issue of the journal, the EchoCRT investigators show, in a prospective randomized controlled trial, that patients(More)
F riedman et al. (1), in this issue of the Journal, compared the outcome of Medicare patients age >65 years with heart failure (HF), an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m, and an apparent indication for cardiac resynchronization therapy (CRT), who received either an implantable cardioverter-defibrillator (ICD) or a cardiac(More)
Cardiac resynchronisation therapy (CRT) is an effective intervention for appropriately selected patients with heart failure, but exactly how it works is uncertain. Recent data suggest that much, or perhaps most, of the benefits of CRT are not delivered by re-coordinating left ventricular dyssynchrony. Atrio-ventricular resynchronization, reduction in mitral(More)
Zeitler et al suggest that implantable cardioverter defibrillators (ICDs) exert a similar reduction in mortality in men and women, but their estimate of the absolute reduction in mortality for either sex (≈7.5% at 1 year and 10% by 3 years) far exceeds that observed (about 0% and 5% at 1 and 3 years, respectively) in randomized controlled trials (RCTs)(More)
PURPOSE There is overwhelming evidence that β-blockers reduce cardiovascular hospitalizations and mortality in patients with heart failure and a reduced left ventricular ejection fraction provide they are in sinus rhythm. However, a recent meta-analysis of individual patient data provides compelling evidence that β-blockers are not effective in patients(More)
  • 1